Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
7.45
-0.05 (-0.67%)
At close: Apr 28, 2026, 4:00 PM EDT
7.60
+0.15 (2.01%)
After-hours: Apr 28, 2026, 6:59 PM EDT
Solid Biosciences Employees
Solid Biosciences had 121 employees as of December 31, 2025. The number of employees increased by 21 or 21.00% compared to the previous year.
Employees
121
Change (1Y)
21
Growth (1Y)
21.00%
Revenue / Employee
n/a
Profits / Employee
-$1,440,702
Market Cap
733.04M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 121 | 21 | 21.00% |
| Dec 31, 2024 | 100 | 12 | 13.64% |
| Dec 31, 2023 | 88 | 1 | 1.15% |
| Dec 31, 2022 | 87 | -17 | -16.35% |
| Dec 31, 2021 | 104 | 34 | 48.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| ARS Pharmaceuticals | 163 |
| Allogene Therapeutics | 152 |
| Absci | 140 |
| Alpha Tau Medical | 121 |
| BridgeBio Oncology Therapeutics | 92 |
| Lexicon Pharmaceuticals | 81 |
| Vor Biopharma | 76 |
SLDB News
- 12 hours ago - Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 14 days ago - Solid Biosciences Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 21 days ago - Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 weeks ago - Solid Biosciences Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 6 weeks ago - Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned - Benzinga
- 6 weeks ago - Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial - GlobeNewsWire
- 7 weeks ago - Solid Biosciences Announces Oversubscribed $240 Million Private Placement - GlobeNewsWire